Pharmacodynamics of Yi Medicine Taruosan on prophase atherosclerosis in golden hamster with hyperlipidemia / 中草药

ABSTRACT

Objective: To observe the effect of water extract from Yi Medicine Taruosan (a prescription of podwer) on prophase atherosclerosis in golden hamster. Methods: The golden hamsters were injected with VD3, while fed with high cholesterol diet. After nine weeks, the models were established successfully. The golden hamsters were devided into model, Simvastatin (4.2 mg/kg), and high- and low-dose (16.8 and 2.1 g/kg) Taruosan water extract groups. The animals were ig administered once daily for 11 weeks, and the animals in the control group were not administered. After administration, the levels of total cholesterol (TC), triacylglycerol (TG), low density lipoprotein cholestorol (LDL-C), and high density lipoprotein cholesferol (HDL-C) and the contents of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), matrix metalloproteinase-9 (MMP-9), and tissue-inhibitor of metalloproteinase-1 (TIMP-1) were analyzed. Carotid histomorphological changes were observed by HE staining. Hepatic lesions were evaluated by liver index. Results: Compared with the model group, the levels of TC, TG, LDL-C, IL-1β, TNF-α, and MMP-9 were reduced, the level of TIMP-1 increased, and the carotid artery and hepatic pathological changes were improved in the other groups. Conclusion: Taruosan has a therapeutic effect on prophase atherosclerosis, which may be due to regulating the lipid metabolism, reducing the level of inflammatory factors, and conditioning the imbalance state of MMP-9/TIMP-1.